|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
BioPhysics Assay Laboratory, Inc. (BioPAL(TM)) Awarded Fast-Track National Institutes of Health (NIH) SBIR Grant For Magnetic Resonance Angiography
10/19/2005 5:09:04 PM
WORCESTER, Mass.--(BUSINESS WIRE)--Aug. 2, 2005--BioPhysics Assay Laboratory (BioPAL), Inc. announced today that the company was awarded a $925,000 Fast-Track Phase I/II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). This grant will allow BioPAL to further develop its patent pending gadolinium-based nanocolloid technology as a contrast agent for magnetic resonance angiography (MRA).
Arteriosclerosis is the major cause of human death in the United States. Currently, the standard diagnostic tool for the evaluation of cardiovascular disease is x-ray angiography. This procedure requires inserting a catheter into the arteries of patients and administering a dye to visualize arterial obstruction. In the United States alone, an estimated 3.3 million angiograms are performed annually at a total cost of over $6 billion. Unfortunately, this diagnostic procedure is highly invasive and has a small but significant death and injury rate.
|
|
|
|
|
|
|
|
|
|
|